Advertisement
Canada markets open in 7 hours 23 minutes
  • S&P/TSX

    21,837.18
    -12.02 (-0.06%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • DOW

    38,790.43
    +75.63 (+0.20%)
     
  • CAD/USD

    0.7372
    -0.0017 (-0.23%)
     
  • CRUDE OIL

    82.47
    -0.25 (-0.30%)
     
  • Bitcoin CAD

    88,269.15
    -4,661.99 (-5.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,160.80
    -3.50 (-0.16%)
     
  • RUSSELL 2000

    2,024.74
    -14.58 (-0.72%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,199.00
    -32.50 (-0.18%)
     
  • VOLATILITY

    14.33
    -0.08 (-0.56%)
     
  • FTSE

    7,722.55
    -4.87 (-0.06%)
     
  • NIKKEI 225

    39,857.09
    +116.69 (+0.29%)
     
  • CAD/EUR

    0.6784
    -0.0008 (-0.12%)
     

FDA raises concerns over Valeant's eye drop

A sign for the headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec June 14, 2016. REUTERS/Christinne Muschi (Reuters)

(Reuters) - Valeant Pharmaceuticals International said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida. The U.S. Food and Drug Administration, in a complete response letter (CRL) regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit. The letter did not identify any efficacy or safety issues with the eye drop, a latanoprostene bunod ophthalmic solution. Valeant said it intends to meet the regulators and resolve these concerns, the company said in a statement. Eye care unit Bausch + Lomb is one of Valeant's core assets and a franchise to build on, billionaire investor and Valeant board member Bill Ackman said last week. (Reporting by Ismail Shakil in Bengaluru; Editing by Sunil Nair)